Sight Sciences, Inc. (NASDAQ:SGHT) Insider Matthew Link Sells 4,889 Shares

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Matthew Link sold 4,889 shares of the firm's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $4.10, for a total transaction of $20,044.90. Following the transaction, the insider owned 832,293 shares in the company, valued at approximately $3,412,401.30. This trade represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Sight Sciences Trading Up 2.3%

SGHT traded up $0.08 during trading on Tuesday, hitting $3.55. 166,363 shares of the company's stock were exchanged, compared to its average volume of 212,899. The company has a current ratio of 10.47, a quick ratio of 9.99 and a debt-to-equity ratio of 0.51. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $8.45. The stock has a 50 day moving average price of $3.71 and a 200 day moving average price of $3.13. The firm has a market cap of $183.54 million, a P/E ratio of -3.62 and a beta of 2.47.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. Sight Sciences had a negative net margin of 63.24% and a negative return on equity of 54.62%. The company had revenue of $17.51 million during the quarter, compared to the consensus estimate of $16.51 million. As a group, analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SGHT. Charles Schwab Investment Management Inc. boosted its stake in shares of Sight Sciences by 4.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 268,250 shares of the company's stock valued at $976,000 after purchasing an additional 11,259 shares during the period. WealthTrust Asset Management LLC purchased a new position in shares of Sight Sciences in the fourth quarter valued at $48,000. American Century Companies Inc. boosted its stake in shares of Sight Sciences by 10.7% in the fourth quarter. American Century Companies Inc. now owns 51,564 shares of the company's stock valued at $188,000 after purchasing an additional 4,964 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Sight Sciences during the 4th quarter valued at $50,000. Finally, JPMorgan Chase & Co. boosted its stake in Sight Sciences by 52.7% during the 4th quarter. JPMorgan Chase & Co. now owns 106,351 shares of the company's stock valued at $387,000 after acquiring an additional 36,691 shares during the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on SGHT shares. Lake Street Capital boosted their price target on shares of Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a research note on Friday, May 9th. Wall Street Zen upgraded Sight Sciences from a "sell" rating to a "hold" rating in a research report on Saturday, June 28th. Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Citigroup restated a "neutral" rating and set a $3.60 target price (up from $3.20) on shares of Sight Sciences in a research report on Thursday, May 22nd. Finally, Piper Sandler restated a "neutral" rating and set a $4.00 target price (up from $3.50) on shares of Sight Sciences in a research report on Wednesday, June 18th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $4.10.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.